About the Authors
- Peter Hoogerhout
-
* E-mail: Peter.Hoogerhout@rivm.nl
Affiliation Department of Vaccinology, Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
- Willem Kamphuis
-
Affiliation Netherlands Institute for Neuroscience (NIN), Astrocyte Biology & Neurodegeneration, Royal Netherlands Academy of Arts and Sciences, Amsterdam, The Netherlands
- Humphrey F. Brugghe
-
Affiliation Department of Vaccinology, Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
- Jacqueline A. Sluijs
-
Affiliation Netherlands Institute for Neuroscience (NIN), Astrocyte Biology & Neurodegeneration, Royal Netherlands Academy of Arts and Sciences, Amsterdam, The Netherlands
- Hans A. M. Timmermans
-
Affiliation Department of Vaccinology, Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
- Janny Westdijk
-
Affiliation Department of Vaccinology, Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
- Gijsbert Zomer
-
Affiliation Department of Vaccinology, Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
- Claire J. P. Boog
-
Affiliation Department of Vaccinology, Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
- Elly M. Hol
-
Affiliation Netherlands Institute for Neuroscience (NIN), Astrocyte Biology & Neurodegeneration, Royal Netherlands Academy of Arts and Sciences, Amsterdam, The Netherlands
- Germie P. J. M. van den Dobbelsteen
-
Affiliation Department of Vaccinology, Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
Competing Interests
The authors have read the journal's policy and have the following conflicts. PH and GPJMvdD have filed a patent application entitled “Vaccine against amyloid folding intermediate.” EP08159385.7 (2008), WO2010002251 (A1) (2010). The RIVM is a Government Institute. The application was filed on behalf of “the Kingdom of The Netherlands.” It does not alter the authors' adherence to the PLoS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: PH WK JW GZ EMH GPJMvdD. Performed the experiments: PH WK HFB JAS HAMT JW GZ. Analyzed the data: PH WK JW GZ CJPB EMH GPJMvdD. Contributed reagents/materials/analysis tools: PH WK HFB JAS HAMT JW GZ. Wrote the paper: PH WK EMH.